In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target, which represents a potential upside of 547% from where the stock is currently trading.
Aschoff noted, “At Repros’ recent Analyst Day, seven KOLs discussed Androxal’s positioning for secondary hypogonadism. Repros will meet with the FDA in early November and plans to submit an NDA around YE14 that contains extensive clinical results. As a non-TRT for secondary hypogonadism, we believe Androxal’s safety data will be the FDA’s key focus. The proposed indication is “oral treatment of hypogonadotrophic hypogonadism (secondary hypogonadism) with preservation of testicular function (sperm concentration >15million/mL and endogenous testosterone production in men with BMI over 25)”, a clear differentiation from TRT labels.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.7% and a 64.0% success rate. Aschoff has a -31.0% average return when recommending RPRX, and is ranked #179 out of 3355 analysts.